Image credit: Canva
Endometrial cancer (EC), also known as cancer of the uterus, is the most common gynecologic cancer in the U.S. In approximately 30% of cases, EC has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. A trial led by Hoyoung M. Maeng, M.D., Associate Research Physician in the Vaccine Branch, is studying the use of combination drug and vaccine therapy for certain patients with HER2-expressing endometrial cancer.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Erica Redmond at (240) 858-3783 or erica.redmond@nih.gov
Clinicaltrials.gov identifier: NCT06253494
NCI Protocol ID: IRB001557
Official Title: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
